Search Results

12 results

  1. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 52

    Biological test procedure for fresh generated cigarette smoke and e-cigarette aerosols under air-liquid interface (ALI) exposure in 24 and 96 multi-well plates

    WIECZOREK R.(1); TRELLES STICKEN E.(1); WALELE T.(2); CZEKALA L.(3); SIMMS L.(3)
    (1) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (2) Fontem Ventures, Amsterdam, The Netherlands; (3) Imperial Tobacco Limited, Bristol, U.K.
    Cigarette smoke and e cigarette aerosol contain particulate matter/liquid droplets in the solid phase as well as volatile substances in the gas phase. Both fractions are of potential toxicological relevance and should be considered when assessing ...
  2. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 53

    Use of human derived cell lines to increase the biological relevance of cigarette condensate, non-tobacco materials and e-liquids testing

    WIECZOREK R.(1); TRELLES STICKEN E.(1); WALELE T.(2); CZEKALA L.(3); SIMMS L.(3)
    (1) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (2) Fontem Ventures, Amsterdam, The Netherlands; (3) Imperial Tobacco Limited, Bristol, U.K.
    The in vitro testing strategy of tobacco products is mainly based on the testing of extracts from cigarette smoke condensates. An accepted industry wide assay battery has been developed over recent years which delivers reliable results for the ...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 08

    Indoor air quality and surface deposition assessment following use of an open system e-cigarette

    BAUER N.(1); TSCHIERSKE N.(1); O'CONNELL G.(2); CAHOURS X.(3)
    (1) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany; (2) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands; (3) SEITA-Imperial Tobacco Limited, Fleury-les-Aubrais, France
    Electronic cigarette (e-cigarette) nicotine delivery devices are growing in popularity worldwide. Both regulators and public health organisations are beginning to examine potential implications that exposure to exhaled e-cigarette aerosol may have on non ...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 21

    The use of in vitro human biomarkers from relevant primary cell lines, to assess the effects of increasing nicotine concentration in e-liquids

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); BERG E.(2); WALELE T.(3)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) DiscoverX Corporation, Fremont, CA, U.S.A.; (3) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    As part of the ongoing stewardship of electronic cigarettes, and in line with the National Academies of Sciences “ Toxicity Testing in the 21st Century: A Vision and a Strategy ”, Fontem Ventures B.V. have investigated the utility of a series of endpoints ...
  5. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, STPOST 18

    Assessment of the so-called “gateway effect” based on electronic vapour product classifications

    VERRON T.(1); CAHOURS X.(1); CERSON L.(2); COLARD S.(1); O’CONNELL G.(3)
    (1) SEITA-Imperial Tobacco, Fleury-les-Aubrais, France; (2) Imperial Tobacco Limited, Bristol, U.K.; (3) Fontem Ventures B.V., Amsterdam, Netherlands
    Since electronic cigarettes (e-cigs) became popular as alternatives to conventional cigarettes, with subsequent market growth amongst smokers, there is currently a debate as to whether e-cigs may be a "gateway" to conventional cigarette smoking ...
  6. TSRC, Tob. Sci. Res. Conf., 2016, 70, abstr. 23

    Reductions in biomarkers of exposure (BoE) to harmful or potentially harmful constituents (HPHCs) following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers

    O’CONNELL G.(1); GRAFF D.W.(2); D’RUIZ C.(3)
    (1) Fontem Ventures B.V, Amsterdam, The Netherlands; (2) Celerion Inc, Lincoln, NE, USA; (3) Fontem Ventures B.V Greensboro, NC, USA
    Changes in fifteen urine, blood and exhaled breath BoEs of HPHCs representing classes of compounds reported by FDA to be significant contributors to smoking-associated disease risks were measured in 105 clinical-confined subjects following randomization ...
  7. CORESTA Congress, Shanghai, 2008, SSPTPOST 11

    Use of an EpiOralTM human tissue model for testing of substances for oral irritancy in vitro

    JAI T.S.; DELVES S.J.; FAUX S.P.; KUMARAVEL T.S.; NEILSON L.R.; MEREDITH C.
    Advanced Technologies Ltd., Cambridge, UK
    The EpiOralTM tissue model consists of normal human keratinocytes differentiated to form a multilayered tissue. The phenotype is analogous to human oral epithelium in vivo providing the opportunity for in vitro irritancy testing on human tissue. This ...